Since 2007, the guideline development process within the World Health Organization (WHO) has
been overseen by the WHO Guidelines Review Committee (GRC), which follows internationally
recognized standards such as the GRADE (Grading of Recommendations Assessment, Development
and Evaluation) approach, to su...
The present guideline update aims to use the best available evidence on the treatment of drug-susceptible TB, as well as on interventions to ensure adequate patient care and support, in order to inform policy decisions made in these technical areas by national TB control programme managers, national poli...
Tuberculosis/drug therapy,
Tuberculosis, Multidrug-Resistant/drug therapy,
Antitubercular Agents/administration & dosage,
Clinical Protocols,
Treatment Outcome,
Fluoroquinolones/administration & dosage,
Rifampin/administration & dosage,
Isoniazid/administration & dosage,
Pyrazinamide/administration & dosage,
Ethambutol/administration & dosage
The specific objectives were to evaluate the harms to benefits ratio of delamanid in combination with the currently recommended MDR-TB treatment regimen in children. Based on this evaluation, to develop recommendations on the use of delamanid as part of WHO-recommended longer MDR-TB treatment regimens, a...
In November 2015, the World Health Organization (WHO) convened a meeting of a Guideline Development Group (GDG) for the update of policy recommendations on the treatment of drug-resistant TB. The GDG was composed of a multidisciplinary group of tuberculosis (TB) and drug-resistant TB experts external to ...
The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient's eligibility criteria and safety ...
Cost-Benefit Analysis,
Tuberculosis, Multidrug-Resistant/drug therapy,
Drug Therapy, Combination,
Nitroimidazoles/therapeutic use,
Treatment Outcome,
Antitubercular Agents/therapeutic use,
Tuberculosis, Pulmonary/drug therapy,
Clinical Trials as Topic,
Nitroimidazoles/economics,
Antitubercular Agents/economics
This Guideline outlines the purpose and the target audience of the second edition of Guidance for national tuberculosis programmes on the management of tuberculosis in children. It discusses the difference between TB in children and adolescents and TB in adults and provides an estimate of the burden of c...
WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis (MDR-TB) occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far...
This 2011 update of Guidelines for the programmatic management of drug-resistant
tuberculosis is intended as a tool for use by public health professionals working in response
to the Sixty-second World Health Assembly’s resolution on prevention and control of
multidrug-resistant tuberculosis and extensi...
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) increasingly occur in resource-constrained settings. In the context of a national response to MDR- and XDR-TB, health workers in TB clinics (in district hospitals and some accredited health centres) will need t...
This document is intended to provide an interim policy framework for the laboratory component relevant to programmatic implementation of MDR-TB strategies....
